Type of Assessment:
Sarcomatoid mesothelioma vs. myogenic sarcoma: a strong case for diagnostic electron microscopy: a case report
Ultrastructural Pathology 2025 May 25 [Link] Nadine H Oury, Katherine Killian D O, Tim D Oury Abstract Mesothelioma is often considered a difficult diagnosis due to its rarity, the wide variety of histological patterns and the propensity of metastasis from cancers of unknown origin to serosal surfaces. The advent of numerous new immunochemical markers has…
Read MoreDual Immunotherapy for Pericardial Mesothelioma That Developed After a Decade-Long Idiopathic Pericarditis: A Case Report
Respirology Case Reports 2024 May 26 [Link] Beatriz Grau Mirete, Paula Rodriguez Paya, Mariano Martinez Marin, Asia Ferrández Arias, Miguel Borregón Rivilla, Antonio David Lazaro Sanchez, Pedro Morillas Blasco, Alvaro Rodriguez-Lescure, Javier David Benítez Fuentes Abstract Malignant pericardial mesothelioma (MPeM) is exceptionally rare, and its association with long-standing idiopathic pericarditis remains unreported. We present a…
Read MoreA four-miRNA signature as a potential biomarker of malignant mesothelioma patients from hand-spinning asbestos exposed area in Eastern China
Ecotoxicology and Environmental Safety 2025 July 1 [Link] Lijin Zhu, Shibo Ying, Xin Su, Wenke Yu, Kaili Yan, Wei Shen, Shuaiyue Hu, Zhaoqiang Jiang, Hailing Xia, Lingfang Feng, Yan Zeng, Junqiang Chen, Xing Zhang, Jianlin Lou Abstract Malignant mesothelioma (MM) is an aggressive malignant tumor of mesothelial origin that develops mainly in the parietal pleura…
Read MoreKEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma
Cancer Science 2025 May 23 [Link] Takashi Kijima, Terufumi Kato, Yasushi Goto, Kozo Kuribayashi, Koji Mikami, Yoshiki Negi, Shuji Murakami, Tatsuya Yoshida, Masae Homma, Akira Wakana, Kazuo Noguchi, Nobukazu Fujimoto Abstract Pleural mesothelioma (PM) is an inflammatory cancer linked with asbestos exposure and has a poor prognosis. We report results of the phase 1b KEYNOTE-A17…
Read MoreFrom asbestos exposure to carcinogenesis: Transcriptomic signatures in malignant pleural mesothelioma
Experimental and Molecular Pathology 2025 May 20 [Link] Diletta Rosati, Bianca Giulia Maurizi, Viola Bianca Serio, Debora Maffeo, Angela Rina, Francesca Mari, Maria Palmieri, Antonio Giordano, Elisa Frullanti Abstract Background: The incidence of malignant pleural mesothelioma (MPM) has surged due to widespread asbestos exposure, particularly since the mid-20th century. Despite significant advancements in cancer treatment,…
Read MoreA bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023
Journal of Thoracic Cancer 2025 April 30 [Link] Sheng Chen, Ce Zhao, Ruiqi Liu, Wenjie Jiao Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor originating from the mesothelial lining of the pleural cavity. It is characterized by extensive nodular pleural thickening and has a propensity to invade the pleural adipose tissue and adjacent…
Read MoreDiagnostic value of cyclin D1 immunohistochemistry in differentiating malignant mesothelioma from reactive mesothelial proliferation
Annals of Diagnostic Pathology 2025 October [Link] Döndü Nergiz, Arsenal Sezgin Alikanoğlu, Dinç Süren Abstract Introduction: Although morphologic assessment carries utmost importance in differentiating malignant mesotheliomas (MM) from reactive mesothelial proliferations (RMP), sometimes it may fail to clearly differentiate between these two entities. The aim of this study is to evaluate the potential role of…
Read MoreBreaking Through: Immunotherapy Innovations in Pleural Mesothelioma
Clinical Lung Cancer 2025 April 22 [Link] Amalia A Sofianidi, Nikolaos K Syrigos, Kevin G Blyth, Andriani Charpidou, Ioannis A Vathiotis Abstract The prognosis of pleural mesothelioma (PM) is poor and conventional chemotherapy regimens have shown limited antitumor activity. Recent use of immune checkpoint inhibitors (ICIs) has shown promise, with CheckMate-743 trial establishing nivolumab plus…
Read MoreDeoxypodophyllotoxin inhibited the growth of malignant pleural mesothelioma by inducing necroptosis and mitotic catastrophe
Phytomedicine 2025 July 25 [Link] Cheng Zhong, Shenqi Wang, Jingyuan Zhang, Qi Zheng, Yuqiong Lei, Yongle Xu, Tao Ren, Rong Sun Abstract Background: Malignant pleural mesothelioma (MPM) is an extremely aggressive cancer with a poor prognosis and limited effective treatment options. However, recent studies have shown that targeting microtubule regulation is a viable approach for…
Read MoreClinical Significance of Tumor-Infiltrating Lymphocytes in Malignant Peritoneal Mesothelioma: A Single-Center Study of 143 Cases
Annals of Surgical Oncology 2025 July [Link] He-Liang Wu, Rui Yang, Xin-Li Liang, Ru Ma, Yan-Dong Su, Zhi-Ran Yang, Yu-Run Cui, Xue-Mei Du, Yi-Tong Liu, Yan Li Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with high mortality rate and extremely poor prognosis. The tumor immune microenvironment, particularly tumor-infiltrating lymphocytes (TILs), plays…
Read More